Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -540.11% | -607.67% | 97.28% | 94.40% | 110.34% |
| Total Depreciation and Amortization | -193.19% | -196.40% | -- | -- | -- |
| Total Amortization of Deferred Charges | 409.19% | 305.11% | 234.15% | -53.31% | -33.69% |
| Total Other Non-Cash Items | 116.69% | 49.68% | 76.41% | 52.51% | -28.19% |
| Change in Net Operating Assets | -167.92% | -161.75% | 349.97% | 373.79% | 984.55% |
| Cash from Operations | -150.71% | -159.62% | 257.38% | 223.63% | 207.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | 2,790.17% | -80.14% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -39.67% | -28.87% | 3.21% | 4.43% | 19.43% |
| Repurchase of Common Stock | -495.00% | -729.87% | -728.21% | -634.83% | 41.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -894.29% |
| Cash from Financing | -350.49% | -328.19% | -305.11% | 149.83% | -76.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -186.66% | -186.93% | 227.23% | 260.90% | 65,239.53% |